Point of view: Thromboembolic risks associated with catheter ablation for atrial fibrillation
|
|
- Ambrose Lee
- 8 years ago
- Views:
Transcription
1 Point of view: Thromboembolic risks associated with catheter ablation for atrial fibrillation Shah, Dipen 1. What is the background of thromboembolic complications in the setting of catheter ablation of atrial fibrillation? Embolic events are a known complication of catheter ablation, indeed of cardiac catheterisation in general but have been infrequent in the era dominated by ablation of paroxysmal supraventricular tachycardias. In the current context of expanding indications of catheter ablation, particularly for atrial fibrillation and to a lesser extent for left atrial flutter and ventricular tachycardia, thromboembolic complications have become commoner. The MERFS survey found a 0.06 % risk of embolic events among 1715 patients right sided ablation procedures (1). A recent world-wide survey of ablation for atrial fibrillation found a 0.94 % embolic event risk amongst 7154 patients undergoing left atrial ablation (2). As opposed to tamponade or local bleeding, an embolic event, particularly within the circulation of the central nervous system can have profound and permanent sequelae. Moreover, the therapeutic options in the event of an embolic event are limited. This is why, I consider an embolic event among the most feared complication of catheter ablation of atrial fibrillation. Certainly, although an atrio-esophageal fistula is even more lethal it is thought to be significantly rarer. Typically, an embolic event occurring during or soon after a catheter ablation procedure is considered a procedural complication. When the procedure is performed with heavy sedation or under general anaesthesia, cerebrovascular embolic events may be difficult to recognise and become apparent only later. Although a definitive time window has not been defined, complications occurring within the first 24 hours after the ablation are almost certainly procedure linked. In the event of cerebrovascular emboli, the use of full dose anticoagulation during and after the procedure increases the risk of aggravation because of secondary hemorrhage 2. What factors contribute to the risk of thromboembolism in the setting of catheter ablation for atrial fibrillation?
2 Factors contributing to the risk of thromboembolism in the above setting may conveniently be considered under three categories: a. Those present before the procedure b. Those operative during the procedure c. Those operative after the procedure. a. Before the procedure, the underlying arrhythmia and underlying (cardiovascular) disease are major factors that determine the likelihood of a pre-existing intracardiac or left atrial thrombus. Atrial fibrillation per se, co-existing risk factors such as age, hypertension, diabetes mellitus, congestive heart failure, and mitral valve disease are all important predictors of the risk of embolic events, although different pathophysiologic mechanisms may be responsible. Atrial fibrillation, congestive heart failure and mitral valve disease are all conditions producing or contributing to intracardiac stasis, whereas hypertension, diabetes mellitus and age probably contribute to acceleration or promotion of the atherosclerotic process, thereby promoting atheroembolic events. b. During the ablation procedure the presence of foreign bodies in the circulation such as catheters, sheaths and guidewires activate the coagulation cascade and promote the development of thrombi. The nature of the foreign surface and its surface area are both probably related to the extent of activation of the coagulation cascade. Additionally, depending on their design, catheters and sheaths produce areas of stasis pockets protected from the flushing effects of blood flow. Typically unperfused sheaths are frequently subject to this problem and prone to develop insitu thrombus. This thrombus may be then pushed out into the circulation by a catheter or by a bolus of flush or simply by restarting an interrupted perfusion flush. Filamentous thrombi attached to the tip of sheaths very likely develop as a result of this mechanism. Further, air emboli can develop because of the sucking effect of withdrawing catheters from sheaths. Air is aspirated through the non-return valves of sheaths which are not designed to be air tight and certainly not to prevent aspiration. As with in situ developing thrombi, these bubbles are pushed out into the circulation by catheters or boluses of flush. Blood proteins heated by tissue or by RF current may also be denatured into macromolecules with embolic potential. Proteins are altered by temperatures exceeding 50 C but in vivo, soft coagulum (a dense mesh of denatured proteins with enmeshed red cells, without any visible fibrin stranding and occurring despite high concentrations of heparin) develops at interface temperatures of C (3).
3 RF catheter ablation can generate embolic material in other ways as well: endothelium damaged by tissue heating activates the coagulation cascade; steam pops within heated tissue produce cratering and the exposed tissue also activates the coagulation cascade. Rarely, catheter fragments, atheroembolic or calcific debris may be embolised during such procedures. c. After the procedure, the tissue lesions produced by RF delivery provide a continuing stimulation of the coagulation cascade probably till full endothelialisation is achieved. The duration of this at-risk period is unclear and although 3 months may be considered a reasonable period, it is possible that endothelialisation is completed much earlier. Mechanical recovery of atrial contractility undoubtedly plays an important role in preventing the development of stasis induced thrombi and at least two factors may be important in this context: the effect of RF lesion produced fibrosis versus the recovery of non-permanently damaged atrial myocardium. As indicated above, the processes of tissue healing may be expected to be completed by 3 months (or perhaps earlier). The reduction of atrial contractility after tachycardia termination atrial stunning - is the second factor that modulates the overall effect on atrial contraction and may last for weeks to months after elimination of the tachycardia. On the other hand, if arrhythmias recur, the recovery from atrial stunning may be expected to be retarded, probably in proportion to the residual arrhythmia burden. 3. How can the risk of thromboembolic complications be minimised? In view of the multiple possible mechanisms of thrombus generation outlined above, three main strategies may be outlined: Pre-procedural detection of pre-existing thrombi or preventing their development Oral anticoagulation (with an INR between 2 and 3) is the most effective treatment measure currently available for patients at risk for thromboembolic events, however even when the INR is carefully maintained within the prescribed range, this treatment does not provide a 100% protection from thrombo-embolic events. The cumulative thrombo-embolic risk in many patients is a combination of atrial fibrillation related stasis as well as athero-embolic (artery to artery emboli) risk with differing responses to oral anticoagulation. In any case, the risk of catheter manipulation
4 dislodging pre-existing thrombi is probably greater than that related to cardioversion (electric or pharmacologic) and in my opinion, justifies the routine pre-procedure use of transesophageal echocardiography despite effective continuous anticoagulation for 4-6 weeks. Although a TEE alone approach has been advocated, I believe a dual layered screening (oral anticoagulation plus TEE) is more effective in reducing embolic complications. Ideally, the TEE should be performed just before the procedure and in particular, any substantial windows of ineffective anticoagulation between the cessation of oral anticoagulation and the procedure should be avoided with the use of Heparin. Of course, in order to permit safer transseptal puncture, IV heparin administration is usually terminated 4-6 hours prior to the procedure. Preventing the development of thrombi or other emboligenic material during the procedure Although there is little hard evidence, heparin is used almost universally during the procedure to the above end. Most laboratories use bolus doses of Heparin while others use a continuous infusion and the choice of one over the other may have more to do with convenience. In my lab, I use a bolus dose of 80 IU/Kg administered intravenously as soon as left atrial access with a long sheath is secured. Thereafter, ACTs are performed at 45 minute intervals and further boluses of IU of heparin administered in order to maintain the ACT between 200 and 250 seconds. There is some evidence in the literature to support the use of higher target ACTs to reduce the thromboembolic risk (4), however it is prudent to remember that the protection provided by Heparin is associated with a bleeding risk, particularly of tamponade. Although some labs administer heparin before the transseptal puncture, we rely on heparinised flush to prevent thrombus development within the sheaths during this period. In my lab, 2000 IU of Heparin is added to 500 cc of normal saline to constitute a continuous perfusate for the side arm of the long sheath. The use of a perfusion pump allows the reliable delivery of cc of heparinised flush per hour inspite of variations in residual lumen resistance typically during catheter exchange. Although retrospective, a single center experience clearly documented the clinical benefit of continuously perfusing left atrial sheaths at this flow rate (5). The use of an open tip irrigated catheter reduces or eliminates the generation of soft coagulum or char on the catheter tip by cooling the interface and diluting the concentration of plasma proteins and is therefore believed to be an important safety measure (6). When using a non-irrigated catheter, enforcing a lower tip electrode temperature is logical although much less effective particularly with large tip catheters. Avoiding pops and the associated cratering is also important
5 and using the lowest effective power generally helps in achieving this aim. We do not add heparin to the irrigation perfusate because the amount of fluid and heparin delivered will then depend upon the duration of ablation making it difficult to maintain a target ACT. Finally, simple measures such as flushing all sheaths and lumen bearing catheters (with heparinised saline) before introduction and aspiration (a passive bleed-out works particularly well for low pressure left atrial sheaths because negative pressure aspiration with a syringe frequently sucks in air through the back-bleed valve) are very effective in avoiding in situ thrombus development within sheaths which could then be embolised by subsequent catheter introduction. Air emboli are a significant but usually benign problem, producing transient ST elevation typically in a right coronary artery distribution (likely because the right coronary ostium is superiorly placed with the patient supine) with infrequent accompanying chest pain. While the typical syndrome resolves within a few minutes, it is possible that such a benign evolution may not always be the case particularly in the presence of significant coronary artery disease. The role of intracardiac echo is unclear: it certainly offers the possibility of very good monitoring during the procedure, however, the ability to titrate RF power using micro-bubble emanation is limited when using the irrigated tip catheter (7). The additional cost, instrumentation and expertise required for its optimal use further weigh against its routine use. Preventing thrombo-embolic complications after the procedure At the end of the procedure, the achievement of hemostasis at puncture sites has to be balanced against the continuation of anticoagulation. Heparin administration is suspended for an hour or two to allow compression to be effective. Hemostasis is simplified if no arterial puncture has been performed (or a small 5Fr- introducer used) and simple compression for a few minutes can be followed by the prompt resumption of IV heparin in therapeutic doses for the next hours, typically till the next day morning. Because the risk of local bleeding as well as tamponade is high during this period, IV heparin is preferable over low molecular weight subcutaneous heparin because of its shorter half-life, the availability of quick ACT or PTT testing and of protamine reversal. Oral anticoagulation is usually restarted the same evening, without a loading dose and low molecular weight heparin is continued after stopping IV heparin till the achievement of an effective INR.
6 4. What are the long-term implications of catheter ablation of atrial fibrillation for thromboembolic complications? There is little if any evidence to support recommendations about the continued use of anticoagulation after catheter ablation of atrial fibrillation. It must be pointed out that even outside the setting of catheter ablation of atrial fibrillation, there are few recommendations concerning the duration of anticoagulant treatment and in general the consensus has been to recommend anticoagulation without further qualification or for at least 4 weeks (8). In the absence of evidence based recommendations, one has to rely on empiric reasoning. Atrial fibrillation being a major risk factor for thromboembolic events, its elimination is expected to reduce but perhaps not eliminate the propensity for this complication particularly when coexisting risk factors (e.g. hypertension, diabetes, age) remain unchanged. However, anticoagulation is not recommended for these risk factors alone. It is therefore reasonable to consider withdrawing anticoagulation for patients who were anticoagulated only in the run-up to ablation in order to diminish the risk of an embolic peri-procedural complication or those in whom, in the absence of atrial fibrillation or sustained atrial arrhythmias, anticoagulation would not have been ordinarily indicated e.g. patients with AF and hypertension. On the other hand, I do not consider it reasonable to withdraw anticoagulation in patients who have echocardiographic evidence of significantly impaired atrial mechanical function inspite of stable sinus rhythm, although it must be acknowledged that we do not yet have universally acceptable and reproducible measures of atrial mechanical function. Clearly, in the presence of other indications for anticoagulation e.g. severe LV dysfunction, prosthetic valves, anticoagulation should be continued and probably indefinitely so. The situation is much more complex when ablation is successfully performed for patients with a prior history of a thromboembolic event attributable to atrial fibrillation. Since such a history constitutes a high risk marker of recurrence and since there is no evidence to prove that eliminating atrial fibrillation eliminates or diminishes this risk, I consider it prudent to continue anticoagulation for a significantly longer period after successful elimination of atrial fibrillation at least a year. This allows additional time for verification of complete elimination of atrial fibrillation, time for complete recovery from stunning and from the effects of ablation. At this point, if both mechanically effective and stable sinus rhythm is convincingly demonstrated, the possibility of discontinuing oral anticoagulation (replaced by Aspirin) can be discussed with the patient. It must not however be forgotten that the limited follow-up presently available indicates a 1-2% late arrhythmia recurrence risk and therefore periodic surveillance for arrhythmia recurrence is probably necessary.
7 References 1. Hindricks G. The multicentre European radiofrequency survey (MERFS): complications of radiofrequency catheter ablation of arrhythmias. Eur Heart J. 1993, 14, Cappato R, Calkins H, Chen SA et al. Worldwide survey on the methods, efficacy and safety of catheter ablation for human atrial fibrillation. Circulation 2005, 111, Yokoyama K, Nakagawa H, Wittkampf FH, Pitha JV, Lazzara R, Jackman WM. Comparison of electrode cooling between internal and open irrigation in radiofrequency ablation lesion depth and incidence of thrombus and steam pop. Circulation 2006, 113(1), Ren JF, Marchlinski FE, Callans DJ et al. Increased intensity of anticoagulation may reduce risk of thrombus during atrial fibrillation ablation procedures in patients with spontaneous echo contrast. J Cardiovasc Electrophysiol 2005, 16: Cauchemez B, Extramiana F, Cauchemez S, Cosson S, Zouzou H, Meddane M, D Allones LR, Lavergne T, Leenhardt A, Coumel P, Houdart E. High flow perfusion of sheaths for prevention of thromboembolic complications during complex catheter ablation in the left atrium. J Cardiovasc Electrophysiol 2004, 15, Demolin JM, Eick OJ, Munch K, Koullick E, Nakagawa H, Wittkampf FHM. Soft thrombus formation in radiofrequency catheter ablation. PACE 2002, 25, Wazni OM, Rosillo A, Marrouche NF, et al. Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: Impact of different anticoagulation regimens and importance of intracardiac echo imaging. J Cardiovasc Electrophysiol 2005, 16: Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation : the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004, 126 (3 suppl) : 429S-456S.
Atrial Fibrillation An update on diagnosis and management
Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationTreatments to Restore Normal Rhythm
Treatments to Restore Normal Rhythm In many instances when AF causes significant symptoms or is negatively impacting a patient's health, the major goal of treatment is to restore normal rhythm and prevent
More informationAtrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with
More informationAtrial Fibrillation Peter Santucci, MD Revised May, 2008
Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial fibrillation (AF) is an irregular, disorganized rhythm characterized by a lack of organized mechanical atrial activity. The atrial rate is
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More informationNational Medicines Information Centre
National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 www.nmic.ie THE CONTEMPORARY MANAGEMENT OF ATRIAL FIBRILLATION VOLUME 12 NUMBER 3 2006
More informationA Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation
Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation
More informationPatient Information Sheet Electrophysiological study
Patient Information Sheet Electrophysiological study Your doctor has recommended performing an electrophysiological study (also called EPS). EPS is a diagnostic procedure designed to test and evaluate
More informationAnticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
More informationRecurrent AF: Choosing the Right Medication.
In the name of God Shiraz E-Medical Journal Vol. 11, No. 3, July 2010 http://semj.sums.ac.ir/vol11/jul2010/89015.htm Recurrent AF: Choosing the Right Medication. Basamad Z. * Assistant Professor, Department
More informationCATHETER ABLATION for ATRIAL FIBRILLATION
CATHETER ABLATION for ATRIAL FIBRILLATION Atrial Fibrillation Clinic Dr. Richard Leather, Dr. Larry Sterns, Dr Paul Novak, Dr. Chris Lane Royal Jubilee Hospital Block 3 rd floor, Rm 343 1952 Bay Street
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationThe Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It?
The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It? Indiana Chapter-ACC 17 th Annual Meeting Indianapolis, Indiana October 19, 2013 Deepak Bhakta MD FACC FACP FAHA FHRS CCDS Associate
More informationACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY
Care Pathway Triage category ATRIAL FIBRILLATION PATHWAY ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY AF/ FLUTTER IS PRIMARY REASON FOR PRESENTATION YES NO ONSET SYMPTOMS OF AF./../ TIME DURATION OF AF
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationAtrial Fibrillation and Ablation Therapy: A Patient s Guide
Atrial Fibrillation and Ablation Therapy: A Patient s Guide ATRIAL FIBRILLATION CENTER AT UNIVERSITY OF ROCHESTER MEDICAL CENTER www.heart.urmc.edu 585-275-4775 INTRODUCTION Our goal at the Atrial Fibrillation
More informationNational Patient Safety Goals Effective January 1, 2015
National Patient Safety Goals Effective January 1, 2015 Goal 1 Improve the accuracy of resident identification. NPSG.01.01.01 Long Term are ccreditation Program Medicare/Medicaid ertification-based Option
More informationNHS FIFE WIDE POLICY - HAEMATOLOGY MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY
MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY The scope of this guideline is to simplify the management of patients on oral anticoagulation undergoing major and minor surgery.
More informationPlanning: Patient Goals and Expected Outcomes The patient will: Remain free of unusual bleeding Maintain effective tissue perfusion Implementation
Obtain complete heath history including allergies, drug history and possible drug Assess baseline coagulation studies and CBC Assess for history of bleeding disorders, GI bleeding, cerebral bleed, recent
More informationAtrial fibrillation (AF) is the most common sustained
Antithrombotic Therapy in Atrial Fibrillation Gregory W. Albers, MD, Chair; James E. Dalen, MD, MPH; Andreas Laupacis, MD; Warren J. Manning, MD; Palle Petersen, MD, DMSc; and Daniel E. Singer, MD Abbreviations:
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationAnticoagulation before and after cardioversion; which and for how long
Anticoagulation before and after cardioversion; which and for how long Sameh Samir, MD Cardiovascular medicine dept. Tanta faculty of medicine Atrial fibrillation goals of management Identify and treat
More informationAtrial Fibrillation (AF) March, 2013
Atrial Fibrillation (AF) March, 2013 This handout is meant to help with discussions about the condition, and it is not a complete discussion of AF. We hope it will complement your appointment with one
More informationNational Patient Safety Goals Effective January 1, 2015
National Patient Safety Goals Goal 1 Nursing are enter ccreditation Program Improve the accuracy of patient and resident identification. NPSG.01.01.01 Use at least two patient or resident identifiers when
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 06/06/2012 Review Date 06/06/2014 Version 1.1 EQIA Yes /
More informationCOVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION
COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION Question: How should the EGBS Coverage Guidance regarding ablation for atrial fibrillation be applied to the Prioritized List? Question source: Evidence
More informationATRIAL FIBRILLATION: Scope of the Problem. October 2015
ATRIAL FIBRILLATION: Scope of the Problem October 2015 Purpose of the Presentation Review the worldwide incidence and prognosis associated with atrial fibrillation (AF) Identify the types of AF, clinical
More informationHot Line Session at European Society of Cardiology (ESC) Congress 2014:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily
More informationPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
More informationNnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
More informationUHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
More informationAtrial Fibrillation The Basics
Atrial Fibrillation The Basics Family Practice Symposium Tim McAveney, M.D. 10/23/09 Objectives Review the fundamentals of managing afib Discuss the risks for stroke and the indications for anticoagulation
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More information9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationAtrial fibrillation. Quick reference guide. Issue date: June 2006. The management of atrial fibrillation
Quick reference guide Issue date: June 2006 Atrial fibrillation The management of atrial fibrillation Developed by the National Collaborating Centre for Chronic Conditions Contents Contents Patient-centred
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationAtrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center
Atrial Fibrillation Based on ESC Guidelines Moshe Swissa MD Kaplan Medical Center Epidemiology AF affects 1 2% of the population, and this figure is likely to increase in the next 50 years. AF may long
More informationManaging the Patient with Atrial Fibrillation
Pocket Guide Managing the Patient with Atrial Fibrillation Updated April 2012 Editor Stephen R. Shorofsky, MD, Ph.D. Assistant Editors Anastasios Saliaris, MD Shawn Robinson, MD www.hrsonline.org DEFINITION
More informationATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014
ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014 Facts 4 million or so people have atrial fibrillation 16 billion dollars spent yearly in USA 30% of strokes attributable to AF and AFL 3-5
More informationWATCHMAN Left Atrial Appendage Closure Device
WATCHMAN Left Atrial Appendage Closure Device Patient Information Guide WATCHMAN Left Atrial Appendage Closure Device PATIENT INFORMATION GUIDE Your doctor has recommended that you consider undergoing
More informationAtrial fibrillation (AF) care pathways. for the primary care physicians
Atrial fibrillation (AF) care pathways for the primary care physicians by University of Minnesota Physicians Heart, October, 2011 Evaluation by the primary care physician: 1. Comprehensive history and
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS,
More informationCatheter Ablation. A Guided Approach for Treating Atrial Arrhythmias
Catheter Ablation A Guided Approach for Treating Atrial Arrhythmias A P A T I E N T H A N D B O O K This brochure will provide an overview of atrial arrhythmias (heart rhythm problems affecting the upper
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationCurrent Management of Atrial Fibrillation DISCLOSURES. Heart Beat Anatomy. I have no financial conflicts to disclose
Current Management of Atrial Fibrillation Mary Macklin, MSN, APRN Concord Hospital Cardiac Associates DISCLOSURES I have no financial conflicts to disclose Book Women: Fit at Fifty. A Guide to Living Long.
More informationManagement of Symptomatic Atrial Fibrillation
Management of Symptomatic Atrial Fibrillation John F. MacGregor, MD, FHRS Associate Medical Director, Cardiac Electrophysiology PeaceHealth St. Joseph Medical Center, Bellingham, WA September 18, 2015
More informationAtrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI
Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI Outline Atrial Fibrillation What is it? What are the associated
More informationInpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
More informationANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY. Guidelines for Use of Intravenous Isoproterenol
ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY Guidelines for Use of Intravenous Isoproterenol Major Indications Status Asthmaticus As a last resort for
More informationDorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More informationAtrial Fibrillation Management Across the Spectrum of Illness
Disclosures Atrial Fibrillation Management Across the Spectrum of Illness NONE Barbara Birriel, MSN, ACNP-BC, FCCM The Pennsylvania State University Objectives AF Discuss the pathophysiology, diagnosis,
More informationLiving with. Atrial Fibrillation
Living with Atrial Fibrillation U nderstanding Atrial Fibrillation An estimated 2.7 million Americans are living with atrial fibrillation (AF). That makes it the most common heart rhythm abnormality in
More informationAtrial Fibrillation. Chapter TWELVE. Daniel M. Witt INTRODUCTION MORBIDITY AND MORTALITY ASSOCIATED WITH AF 1,3
Chapter TWELVE Atrial Fibrillation Daniel M. Witt 12 INTRODUCTION Atrial fibrillation (AF) is a common cardiac rhythm disorder. While AF rarely causes life-threatening hemodynamic compromise, it is an
More informationPalpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust
Palpitations & AF Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations Frequent symptom Less than 50% associated with arrhythmia
More informationCHADS score of 5 or 6 Recent (within 3mo) stroke or TIA Rheumatic valvular heart disease CHADs score of 3 or 4
LAMC Department of Pharmacy Services: ANTICOAGULATION: Surgical Intervention Table 1: Classification of Surgical interventions according to bleeding risk t required to discontinue anticoagulation Dental
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationTABLE 1 Clinical Classification of AF. New onset AF (first detected) Paroxysmal (<7 days, mostly < 24 hours)
Clinical Practice Guidelines for the Management of Patients With Atrial Fibrillation Deborah Ritchie RN, MN, Robert S Sheldon MD, PhD Cardiovascular Research Group, University of Calgary, Alberta Partly
More information2. ATRIAL FIBRILLATION. Arleen Brown, MD
2. ATRIAL FIBRILLATION Arleen Brown, MD The quality indicators for atrial fibrillation were developed from recent reviews (Pritchett, 1992; Kudenchuk, 1996); results from the Framingham Study (Wolf, 1978;
More informationAtrial Fibrillation: Drugs, Ablation, or Benign Neglect. Robert Kennedy, MD October 10, 2015
Atrial Fibrillation: Drugs, Ablation, or Benign Neglect Robert Kennedy, MD October 10, 2015 Definitions 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary.
More informationBlood thinning (anticoagulation) in atrial fibrillation (AF)
AF A Blood thinning (anticoagulation) in atrial fibrillation (AF) Providing information, support and access to established, new or innovative treatments for atrial fibrillation www.afa.org.uk Registered
More informationListen to Your Heart. What Everyone Needs To Know About Atrial Fibrillation & Stroke. The S-ICD System. The protection you need
Listen to Your Heart The S-ICD System What Everyone Needs To Know About Atrial Fibrillation & Stroke The protection you need without Stroke. touching Are you your at heart risk? Increase your knowledge.
More informationSurgeons Role in Atrial Fibrillation
Atrial Fibrillation Surgeons Role in Atrial Fibrillation Steven J Feldhaus, MD, FACS 2015 Cardiac Symposium September 18, 2015 Stages of Atrial Fibrillation Paroxysmal (Intermittent) Persistent (Continuous)
More informationAddendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter
22 July 2010 EMA/CHMP/EWP/213056/2010 Addendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter Draft Agreed by Efficacy Working Party July 2008 Adoption by CHMP for release
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationRome, Italy December 4-7, 2012 Rome Cavalieri TIMETABLE
Rome, Italy December 4-7, 2012 Rome Cavalieri Monday, December 3 ROOM Terrazza Monte Mario PATIENT MANAGEMENT CONCEPTS AND CONTROVERSIES IN ELECTROPHYSIOLOGY BIOTRONIK International Fellows Program (IFP)
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationWhat to Know About. Atrial Fibrillation
Atrial Fibrillation What to Know About Atrial Fibrillation Understanding Afib Atrial fibrillation, or Afib, is a condition in which the heart beats irregularly speeding up or slowing down, or beating too
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationBackgrounder. Current anticoagulant therapies
Backgrounder Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Current anticoagulant therapies Anticoagulant drugs have significantly reduced the risk of thromboembolic events
More informationManagement of Pacing Wires After Cardiac Surgery
Management of Pacing Wires After Cardiac Surgery David E. Lizotte, Jr. PA C, MPAS, FAPACVS President, Association of Physician Assistants in Cardiovascular Surgery Conflicts: None Indications 2008 Journal
More informationClinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
More informationA Patient Guide to Atrial Fibrillation and Catheter Ablation
A Patient Guide to Atrial Fibrillation and Catheter Ablation Al-Sabah Arrhythmia Institute 1111 Amsterdam Avenue New York, NY 10025 Phone: 212-523-2400 Fax: 212-523-2571 www.stlukescardiology.org Printed
More informationA focus on atrial fibrillation
A focus on atrial fibrillation Is being female really a risk factor for stroke? Dr Justin Mariani MBBS BMedSci PhD FRACP FCSANZ Consultant Cardiologist and Interventional Heart Failure Specialist Alfred
More informationNICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation 1
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More informationAtrial Fibrillation Cardiac rate control or rhythm control could be the key to AF therapy
Cardiac rate control or rhythm control could be the key to AF therapy Recent studies have proven that an option of pharmacologic and non-pharmacologic therapy is available to patients who suffer from AF.
More informationBayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
More informationCardioversion for. Atrial Fibrillation. Your Heart s Electrical System Cardioversion Living with Atrial Fibrillation
Cardioversion for Atrial Fibrillation Your Heart s Electrical System Cardioversion Living with Atrial Fibrillation When You Have Atrial Fibrillation You ve been told you have a heart condition called atrial
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationCTA OF THE EXTRACORONARY HEART
CTA OF THE EXTRACORONARY HEART Charles White MD Director of Thoracic Imaging Department of Radiology University of Maryland NO DISCLOSURES CWHITE@UMM.EDU CARDIAC CASE DISTRIBUTION Coronary CTA 30% ED chest
More informationTachyarrhythmias (fast heart rhythms)
Patient information factsheet Tachyarrhythmias (fast heart rhythms) The normal electrical system of the heart The heart has its own electrical conduction system. The conduction system sends signals throughout
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationAblation For Atrial Fibrillation. Bill Petrellis Electrophysiologist
Ablation For Atrial Fibrillation Bill Petrellis Electrophysiologist AF is the most common arrhythmia in the Western world Prevalence 1.1% in Australia conservative estimate - 240,000 June 2009 AF is an
More informationNOAC S For Stroke Prevention in. Atrial Fibrillation. Peter Cohn M.D FACC Associate Physician in Chief Cardiovascular Care Center Southcoast Health
NOAC S For Stroke Prevention in Atrial Fibrillation Peter Cohn M.D FACC Associate Physician in Chief Cardiovascular Care Center Southcoast Health New Oral Anti Coagulant Formal Definition: Atrial Fibrillation
More informationAtrial Fibrillation (AF) Explained
James Paget University Hospitals NHS Foundation Trust Atrial Fibrillation (AF) Explained Patient Information Contents What are the symptoms of atrial fibrillation (AF)? 3 Normal heartbeat 4 How common
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationATRIAL FIBRILLATION IN THE 21 ST CENTURY TIMOTHY DOWLING, D.O. FAMILY PHYSICIAN
ATRIAL FIBRILLATION IN THE 21 ST CENTURY TIMOTHY DOWLING, D.O. FAMILY PHYSICIAN GOALS AND OBJECTIVES At The end of this talk you should understand: What is Atrial Fibrillation Causes of Atrial Fibrillation
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013 General Principles: There is compelling data in the medical literature to support
More informationAtrioventricular (AV) node ablation
Patient information factsheet Atrioventricular (AV) node ablation The normal electrical system of the heart The heart has its own electrical conduction system. The conduction system sends signals throughout
More informationChristopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona
Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Areas to be covered Historical, current, and future treatments for various cardiovascular disease: Atherosclerosis (Coronary
More informationIntroduction to Electrophysiology. Wm. W. Barrington, MD, FACC University of Pittsburgh Medical Center
Introduction to Electrophysiology Wm. W. Barrington, MD, FACC University of Pittsburgh Medical Center Objectives Indications for EP Study How do we do the study Normal recordings Abnormal Recordings Limitations
More information